[go: up one dir, main page]

ECSP14030537A - Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 - Google Patents

Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1

Info

Publication number
ECSP14030537A
ECSP14030537A ECIEPI201430537A ECPI201430537A ECSP14030537A EC SP14030537 A ECSP14030537 A EC SP14030537A EC IEPI201430537 A ECIEPI201430537 A EC IEPI201430537A EC PI201430537 A ECPI201430537 A EC PI201430537A EC SP14030537 A ECSP14030537 A EC SP14030537A
Authority
EC
Ecuador
Prior art keywords
abl1
bcr
activity
abl2
inhibition
Prior art date
Application number
ECIEPI201430537A
Other languages
English (en)
Inventor
Fabrice Gallou
Bernard Riss
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48444372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14030537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP14030537A publication Critical patent/ECSP14030537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se ref iere a los compuestos de la fórmula ( I ) : en donde Y, Y1 , R1 , R2, R3 y R4 se def inen en la Breve Descr ipción de la Invención; capaces de inhibi r la act ividad de BCR-ABL1 y los mutantes de los mismos. La invención proporciona además un proceso para la preparación de los compuestos de la invención, las preparaciones farmacéut icas que comprenden estos compuestos, y los métodos para ut i l izar tales compuestos en el t ratamiento de cánceres.
ECIEPI201430537A 2012-05-09 2014-12-08 Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 ECSP14030537A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261644616P 2012-05-09 2012-05-09

Publications (1)

Publication Number Publication Date
ECSP14030537A true ECSP14030537A (es) 2015-09-30

Family

ID=48444372

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201430537A ECSP14030537A (es) 2012-05-09 2014-12-08 Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1

Country Status (24)

Country Link
US (2) US20150087808A1 (es)
EP (1) EP2847211A1 (es)
JP (3) JP2015517481A (es)
KR (1) KR20150006435A (es)
CN (2) CN108715606A (es)
AR (1) AR090964A1 (es)
AU (2) AU2013257989A1 (es)
BR (1) BR112014027648A2 (es)
CA (1) CA2868940A1 (es)
CL (1) CL2014003014A1 (es)
CO (1) CO7141428A2 (es)
EA (1) EA024903B1 (es)
EC (1) ECSP14030537A (es)
HK (1) HK1202555A1 (es)
IL (1) IL235428A0 (es)
IN (1) IN2014DN08483A (es)
MA (1) MA20150231A1 (es)
MX (1) MX2014013613A (es)
PE (1) PE20142433A1 (es)
PH (1) PH12014502499A1 (es)
SG (1) SG11201406303XA (es)
TN (1) TN2014000411A1 (es)
TW (1) TW201350508A (es)
WO (1) WO2013167703A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693820A (zh) * 2014-11-27 2016-06-22 武汉药明康德新药开发有限公司 一种降解环孢菌素a的方法
EP3623378B1 (en) 2017-05-12 2025-07-02 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT401177B (de) 1993-10-22 1996-07-25 Biochemie Gmbh Verfahren zur herstellung von 7-amino-3-cephem-4-carbonsäure-derivaten
CA2335903C (fr) * 1998-07-01 2009-11-10 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
DK1150999T3 (da) * 1999-02-05 2006-10-30 Debiopharm Sa Cyclosporinderivater og fremgangsmåde til fremstilling deraf
CA2444278C (en) * 2001-04-20 2011-11-22 Debiopharm S.A. Modified cyclosporine which can be used as a pro-drug and use thereof
ES2266564T3 (es) * 2001-10-19 2007-03-01 Isotechnika Inc. Sintesis de analogos de cicloporinas.
TW200505946A (en) 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
HRP20110169T1 (hr) * 2004-10-01 2011-04-30 Debiopharm S.A. Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
WO2006063470A1 (en) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites of cyclosporin analogs
CA2674296C (en) 2007-01-04 2015-11-24 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
CA2700536A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
US7910378B2 (en) * 2007-12-14 2011-03-22 Siemens Healthcare Diagnostics Inc. Methods for detection of hydrophobic drugs
WO2009098533A1 (en) 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
KR20110093858A (ko) 2008-11-06 2011-08-18 데비오 레쉑쉐 빠르마슈띠끄 에스.아 시클로운데카뎁시펩티드 화합물 및 약제로서 상기 화합물의 용도
CA2748389A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
AU2010208071C1 (en) * 2009-01-30 2013-06-20 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2012021796A2 (en) * 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection

Also Published As

Publication number Publication date
PE20142433A1 (es) 2015-02-02
KR20150006435A (ko) 2015-01-16
PH12014502499A1 (en) 2014-12-22
IL235428A0 (en) 2014-12-31
AR090964A1 (es) 2014-12-17
EP2847211A1 (en) 2015-03-18
MA20150231A1 (fr) 2015-07-31
EA201492036A1 (ru) 2015-02-27
JP2015517481A (ja) 2015-06-22
CN108715606A (zh) 2018-10-30
CL2014003014A1 (es) 2015-03-06
TW201350508A (zh) 2013-12-16
CA2868940A1 (en) 2013-11-14
AU2016222370A1 (en) 2016-09-15
IN2014DN08483A (es) 2015-05-08
MX2014013613A (es) 2015-02-12
WO2013167703A9 (en) 2014-11-20
CO7141428A2 (es) 2014-12-12
EA024903B1 (ru) 2016-10-31
JP2020033349A (ja) 2020-03-05
AU2013257989A1 (en) 2014-10-23
US9840534B2 (en) 2017-12-12
HK1202555A1 (en) 2015-10-02
CN104284902A (zh) 2015-01-14
AU2016222370B2 (en) 2017-10-05
TN2014000411A1 (en) 2015-12-21
WO2013167703A1 (en) 2013-11-14
US20160304554A1 (en) 2016-10-20
BR112014027648A2 (pt) 2017-06-27
SG11201406303XA (en) 2014-11-27
US20150087808A1 (en) 2015-03-26
JP2018035154A (ja) 2018-03-08

Similar Documents

Publication Publication Date Title
DOP2014000256A (es) Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1
BR112014027181A2 (pt) derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
IN2014MN01754A (es)
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MX2015009057A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim.
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CR20130371A (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
NZ703162A (en) Heterocyclic modulators of lipid synthesis
IN2014MN02106A (es)
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
ECSP14030537A (es) Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1
CU20100250A7 (es) Compuestos pirazólicos 436